<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Children with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 (NF1) undergo costly surveillance scanning for a variety of asymptomatic central <z:mp ids='MP_0008912'>nervous</z:mp> system lesions whose natural history is poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a 20-year retrospective chart review of 25 patients with clinically proven NF1 who required surgery (group A) and contrasted this cohort with 150 NF1 patients who did not require surgery (group B) </plain></SENT>
<SENT sid="2" pm="."><plain>In group A, 52% of patients underwent multiple procedures for more than one lesion (p = 0.043) </plain></SENT>
<SENT sid="3" pm="."><plain>Group A patients were further distinguished from those in group B by exhibiting a greater number of <z:hpo ids='HP_0009734'>optic gliomas</z:hpo> (p = 0.015), nonoptic <z:e sem="disease" ids="C1527390" disease_type="Neoplastic Process" abbrv="">intracranial tumors</z:e> (p = 0.006), cranial nerve (p = 0.000), paraspinal (p = 0.0062), craniofacial (p = 0.001) and visceral (p = 0.03) <z:hpo ids='HP_0001067'>neurofibromas</z:hpo> and <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya disease</z:e> (p = 0.00), as well as a higher frequency of <z:hpo ids='HP_0001250'>seizure</z:hpo> disorder, sphenoid wing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and poor academic performance </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="33375">Gadolinium</z:chebi> enhancement occurred in 43% of <z:hpo ids='HP_0009734'>optic gliomas</z:hpo>, 50% of parenchymal <z:hpo ids='HP_0009733'>gliomas</z:hpo>, 100% of cranial nerve, 100% of plexus, 67% of paraspinal, 50% of craniofacial and 50% of visceral <z:hpo ids='HP_0001067'>neurofibromas</z:hpo> in group A, while only 1 group B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> enhanced </plain></SENT>
<SENT sid="5" pm="."><plain>In group A, radiological progression occurred after a median of 4 years from initial diagnosis for <z:hpo ids='HP_0009734'>optic gliomas</z:hpo> as well as cranial nerve, plexus and visceral <z:hpo ids='HP_0001067'>neurofibromas</z:hpo>, 2 years for <z:hpo ids='HP_0006751'>paraspinal neurofibromas</z:hpo> and <z:hpo ids='HP_0010796'>brainstem gliomas</z:hpo> and 2.7 years for craniofacial <z:hpo ids='HP_0001067'>neurofibromas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Only 1 tumor progressed in group B </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, a small subgroup of NF1 patients (12.5%) who require treatment are at risk of subsequently needing further surgical attention, whereas a larger group of NF1 patients (87.5%) carry an indolent form of the disease </plain></SENT>
<SENT sid="8" pm="."><plain>We recommend imaging for asymptomatic, <z:chebi fb="0" ids="33375">gadolinium</z:chebi>-enhancing lesions every 2 years for optic pathway and parenchymal <z:hpo ids='HP_0009733'>gliomas</z:hpo> and cranial nerve and visceral <z:hpo ids='HP_0001067'>neurofibromas</z:hpo>, and every year for <z:hpo ids='HP_0010796'>brainstem gliomas</z:hpo> and paraspinal as well as craniofacial <z:hpo ids='HP_0001067'>neurofibromas</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Nonenhancing optic pathway lesions could be followed up radiographically much less often since they do not show progression </plain></SENT>
</text></document>